SAN DIEGO – A National Institutes of Health-funded International Diabetes Closed Loop Trial starting later this year will combine technologies from Tandem Diabetes Care, Dexcom and TypeZero Technologies. “The integration of technology provided by Tandem, Dexcom and TypeZero in this trial represents a new level of sophistication in artificial pancreas research and development,” said Boris Kovatchev, Ph.D., director of the Center for Diabetes Technology at the University of Virginia and principal investigator of the trial. A Tandem insulin pump and Dexcom G5 sensor will be included as part of a blood glucose control system that combines these devices with a smartphone running TypeZero’s inControl closed loop algorithm. The companies anticipate that the integrated design, together with data from the IDCL Trial, will be the basis for a future regulatory submission by Tandem. The trial will enroll 240 adults with Type 1 diabetes.
You are here: / / Tech vendors team up for closed loop trial